This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1imr

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (07:36, 7 February 2024) (edit) (undo)
 
(6 intermediate revisions not shown.)
Line 1: Line 1:
 +
==MOLECULAR STRUCTURE OF THE HALOGENATED ANTI-CANCER DRUG IODODOXORUBICIN COMPLEXED WITH D(TGTACA) AND D(CGATCG)==
==MOLECULAR STRUCTURE OF THE HALOGENATED ANTI-CANCER DRUG IODODOXORUBICIN COMPLEXED WITH D(TGTACA) AND D(CGATCG)==
-
<StructureSection load='1imr' size='340' side='right' caption='[[1imr]], [[Resolution|resolution]] 1.60&Aring;' scene=''>
+
<StructureSection load='1imr' size='340' side='right'caption='[[1imr]], [[Resolution|resolution]] 1.60&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>[[1imr]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1IMR OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1IMR FirstGlance]. <br>
+
<table><tr><td colspan='2'>[[1imr]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1IMR OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1IMR FirstGlance]. <br>
-
</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=DM7:4-DEOXY-4-IODODOXORUBICIN'>DM7</scene><br>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.6&#8491;</td></tr>
-
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1imr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1imr OCA], [http://www.rcsb.org/pdb/explore.do?structureId=1imr RCSB], [http://www.ebi.ac.uk/pdbsum/1imr PDBsum]</span></td></tr>
+
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DM7:4-DEOXY-4-IODODOXORUBICIN'>DM7</scene></td></tr>
-
<table>
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1imr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1imr OCA], [https://pdbe.org/1imr PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=1imr RCSB], [https://www.ebi.ac.uk/pdbsum/1imr PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1imr ProSAT]</span></td></tr>
-
<div style="background-color:#fffaf0;">
+
</table>
-
== Publication Abstract from PubMed ==
+
-
4'-Deoxy-4'-iododoxorubicin, a halogenated anthracycline derivative, is an anticancer agent currently under Phase II clinical trials. In preclinical studies, it has demonstrated significantly reduced levels of cardiotoxicity compared to currently employed anthracyclines. It also has modified pharmacological properties resulting in an altered spectrum of experimental antitumor activity. The iodine atom at the 4' position of the sugar ring reduces the basicity and enhances the lipophilicity of this compound as compared to related anthracycline drugs. We report here single crystal X-ray diffraction studies of the complexes of 4'-deoxy-4'-iododoxorubicin with the hexanucleotide duplex sequences d(TGTACA) and d(CGATCG) at 1.6 and 1.5 A, respectively. The iodine substituent does not alter the geometry of intercalation as compared to previously solved anthracycline complexes, but appears to markedly affect the solvent environment of the structures. This could have consequences for the interaction of this drug with DNA and DNA binding proteins in cells.
+
-
 
+
-
Molecular structure of the halogenated anti-cancer drug iododoxorubicin complexed with d(TGTACA) and d(CGATCG).,Berger I, Su L, Spitzner JR, Kang C, Burke TG, Rich A Nucleic Acids Res. 1995 Nov 11;23(21):4488-94. PMID:7501474<ref>PMID:7501474</ref>
+
-
 
+
-
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
+
-
</div>
+
-
== References ==
+
-
<references/>
+
__TOC__
__TOC__
</StructureSection>
</StructureSection>
-
[[Category: Berger, I.]]
+
[[Category: Large Structures]]
-
[[Category: Burke, T G.]]
+
[[Category: Berger I]]
-
[[Category: Kang, C.]]
+
[[Category: Burke TG]]
-
[[Category: Rich, A.]]
+
[[Category: Kang C]]
-
[[Category: Spitzner, J R.]]
+
[[Category: Rich A]]
-
[[Category: Su, L.]]
+
[[Category: Spitzner JR]]
-
[[Category: Complexed with drug]]
+
[[Category: Su L]]
-
[[Category: Dna]]
+
-
[[Category: Double helix]]
+
-
[[Category: Right handed dna]]
+

Current revision

MOLECULAR STRUCTURE OF THE HALOGENATED ANTI-CANCER DRUG IODODOXORUBICIN COMPLEXED WITH D(TGTACA) AND D(CGATCG)

PDB ID 1imr

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1imr"
Personal tools